Meibomian gland disease and reimbursement – Ophthalmology Management
Treatment of meibomian gland dysfunction (MGD) is garnering increased interest, but you need to consider reimbursement issues.
This article answers the following questions:
- What treatments are available for MGD?
- What documentation is required to support treatment?
- How is this treatment reimbursed?
- What CPT code applies: 67700 or 0207T?
What is meibomian gland dysfunction?
This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Executive Vice-President, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below: